Home Page
Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.